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Abstract
Introduction: Desmoid tumor is characterized by infiltrative growth and local recurrence often occurs after
surgery. To reduce the local recurrence rate, adjuvant therapy, such as radiotherapy and pharmacotherapy with
cytotoxic agents, anti-estrogen agents and non-steroidal anti-inflammatory drugs, is often applied. In addition,
these non-surgical treatments are also performed in patients with unresectable desmoid tumors. We successfully
treated a patient with a desmoid tumor with tranilast; an anti-allergic agent.
Case presentation: A 48-year-old Japanese man with a slow-growing desmoid tumor on his chest wall was
treated with an oral administration of tranilast (300 mg per day, three times a day). Two years and two months
after the commencement of his therapy, the tumor became impalpable. At this time, the oral administration of
tranilast was discontinued. Two years after discontinuation of the treatment, a physical examination showed no
recurrence of the tumor and he continued in a state of remission. We were successfully able to reduce the size of
the tumor and thereafter maintain the reduced size.
Conclusion: Tranilast was clinically effective in our case, and is probably comparable to cytotoxic agents or anti-
estrogen agents. Because tranilast has substantially fewer adverse effects than cytotoxic agents, it could be a very
useful therapeutic agent for desmoid tumor.
Introduction
Desmoid tumor, defined as clonal fibroblastic prolifera-
tion, arises in the deep soft tissue and is characterized
by infiltrative growth and a tendency towards local
recurrence but without the ability to metastasize. The
standard and definitive treatment for desmoid tumor is
wide excision, and adjuvant radiotherapy is sometimes
applied. Although neither distant metastasis nor malig-
nant transformation occurs, the reported local recur-
rence rate after excision is high: the local recurrence
rate today is approximately 50 percent [1]. Pharma-
cotherapy, with cytotoxic agents, anti-estrogen agents or
non-steroidal anti-inflammatory drugs (NSAIDs), is per-
formed in addition to radiotherapy for both recurrent
tumors and unresectable tumors. The efficacy of the
pharmacotherapy is variable but its adverse effects are
significant. Therefore, a possible new kind of pharma-
cotherapy with minimal adverse effects is desirable.
Desmoid tumors and keloids have common histologi-
cal features where fibroblasts proliferate abnormally and
abundant collagen fibers deposit locally. We hypothe-
sized that tranilast, a therapeutic agent for keloid and
hypertrophic scars, might be effective for desmoid
tumors. We report the case of a patient with desmoid
tumor on his chest wall whom we treated with tranilast.
We were successfully able to reduce the size of the
tumor and thereafter maintain the reduced size. To the
best of our knowledge, there has been no reported case
of desmoid tumor treated with tranilast.
Case presentation
A 48-year-old Japanese man noticed a slightly tender
soft tissue mass on the anterolateral aspect of the lower
part of his left chest wall, six months prior to his first
visit to our hospital. When the tumor became slightly
enlarged, he visited his previous orthopedist. A soft tis-
sue tumor was suspected and an incisional biopsy was
performed. However, a definite pathological diagnosis
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specimen. He was referred to our hospital for further
examination and treatment. On inspection, the antero-
lateral surface of the lower part of his left chest wall was
swollen. On palpation, a fibrously hard tumor, measur-
ing 5 × 6 cm, was palpable. It adhered firmly to the
chest wall. He was experiencing mild pain. There was
no localized heat or redness. Chest radiographs showed
no abnormal findings. A magnetic resonance imaging
(MRI) scan showed that the soft tissue tumor (measur-
ing 6 × 5.5 × 5 cm) was located beneath his external
oblique muscle and permeated into his intercostal mus-
cles, causing the peritoneum to protrude towards his
abdominal space (Figure 1a, b). The signal intensity of
the lesion was isointense to skeletal muscle on T1-
weighted images (Figure 1a) and heterogeneously high
on T2-weighted images with some areas of low intensity
(Figure 1b). The lesion was strongly enhanced by the
administration of a contrast medium (Figure 1c). As a
result of these physical and MRI findings, we suspected
a soft tissue tumor rich in collagen fibers and blood ves-
sels, such as desmoid tumor, fibrosarcoma or malignant
fibrous histiocytoma. He was unwilling to take a second
biopsy and a natural course was observed. The tumor
gradually enlarged, becoming 8 × 6 cm on palpation ten
months after his first visit. At this time, a second
incisional biopsy was performed. Macroscopically, the
tumor was whitish and fibrous. Histologically, the tumor
was poorly circumscribed and infiltrated into his sur-
rounding soft tissue. Spindle or stellate-shaped cells of
uniform appearance proliferated in a collagenous stroma
(Figure 2). The nuclei were slightly irregular but lacked
hyperchromasia or atypia and had small nucleoli. The
mitotic rate was less than 1 per 10 high power field
(HPF). From these histological findings, we made the
diagnosis of desmoid tumor. A wide excision of the
tumor, combined with his ribs and peritoneum, was
planned. However, he refused to undergo surgery. In
addition, he also refused to undergo radiotherapy and
chemotherapy with cytotoxic agents. As an alternative,
we commenced pharmacotherapy with tranilast (Riza-
ben®, Kissei Pharmaceutical Co., Matsumoto City,
Japan). Tranilast was administered orally every day (300
mg per day, three times a day). Immediately after com-
mencement of the therapy, the size of the tumor did
not change and the tumor seemed stabilized. Six months
after initiation of the therapy, the tumor size began to
decrease. Two years and two months after commence-
ment of the therapy, the tumor became impalpable. At
this time, the oral administration of tranilast was discon-
tinued. Two years after the discontinuation of treatment,
a physical examination showed no recurrence of the
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Figure 1 Axial MRI of the chest wall at his first visit. T1-weighted image (a) shows isosignal intensity area, whereas T2-weighted image (b)
shows high intensity area. The tumor is strongly enhanced on gadolinium-enhanced T1-weighted image (c). Arrows indicate the tumor.
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revealed that the tumor still existed, but it was shrunken
in size and the protrusion of the peritoneum towards his
abdominal space seen on his first visit was no longer
evident (Figure 3a, b). T2-weighted images (Figure 3b)
showed that the proportion of low-signal intensity area
was much larger than that seen on his first visit, sug-
gesting a decrease in the tumor’s cellular component.
Discussion
Desmoid tumor is a slow-growing, permeative tumor,
uniformly composed of fibroblasts and abundant col-
lagen. Desmoid tumor of the abdominal wall mostly
occurs in women during pregnancy or soon after deliv-
ery, whereas extra-abdominal desmoid tumor is more
frequent from puberty to 50 years of age, with both
men and women equally affected. The principal site of
extra-abdominal desmoid tumor is the musculature of
the shoulder, followed by the chest wall and back, the
thigh, and then the head and neck [2].
The conventional treatment for extra-abdominal des-
moid tumor is surgery. If practical, surgical excision
with a wide margin is the definitive treatment for des-
moid tumors. The high recurrence rate after excision is
partly due to an inadequate surgical margin for tumors
of such an infiltrative nature [1]. When excision with an
200 µm
Figure 2 Photomicrograph of the biopsy specimen: spindle or stellate-shaped cells are uniformly proliferating in a collagenous
stroma with no nuclear atypia (hematoxylin and eosin stain). Scale bar indicates 200 μm.
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Figure 3 Axial MRI of the chest wall after treatment with tranilast. The tumor on T1-weighted image (a) is smaller than that seen on his
first visit (shown in Figure 1(a)). The proportion of low-signal intensity area on T2-weighted image (b) is larger than that seen on his first visit
(shown in Figure 1b). Arrows indicate the tumor.
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therapy is considered [3]. When the tumor is unresect-
able because of its location or size, radiotherapy may be
performed. Because radiotherapy can induce secondary
sarcoma, and because desmoid tumor occurs mainly in
patients under 40 years of age, it should be avoided if
possible. Like radiotherapy, chemotherapy may be per-
formed after excision as an adjuvant therapy or as a
main therapy for unresectable tumors. Treatment with
chemotherapy has been reported in combination with
various cytotoxic agents; low-dose methotrexate and
vinblastine [4], cyclophosphamide and doxorubicin [5],
mitomycin, doxorubicin and cisplatin [5] and ifosfamide
and etoposide [5]. NSAIDs, such as indomethacin and
sulindac, are also effective. Although there are a high
number of case reports where NSAIDs were effective in
the treatment of desmoid tumor, there have been only a
few reports where their efficacy was discussed in rela-
tion to a significant number of patients [6]. Estrogen
receptor has been found to exist in desmoid tumors,
and anti-estrogen therapy with tamoxifen has been
reported to be effective in some patients [7]. It has been
reported that combined pharmacotherapy with sulindac
and tamoxifen is effective in 70 percent of patients with
desmoid tumor [8]. However, cytotoxic agents have sig-
nificant adverse effects and the selection of patients for
treatment is important. Likewise, anti-estrogen agent is
potentially hazardous to endocrine systems, especially in
premenopausal patients. If NSAIDs are administered for
a long period, they often cause peptic ulcers and renal
disturbances. Therefore, a new modality of pharma-
cotherapy with significantly fewer adverse effects is a
desirable option.
In our case report, tranilast was clinically very effective
and probably comparable to cytotoxic agents or to anti-
estrogen agents. Not only was the tumor size reduced,
but the proportion of high-signal intensity area on a T2-
weighted MRI also became much smaller after the treat-
ment with tranilast. Presumably, a second-look biopsy
would reveal a reduction in the tumor’s cellular compo-
nent. Tranilast was originally developed as a therapeutic
agent for bronchial asthma. In addition, it is effective for
allergic rhinitis, atopic dermatitis and allergic conjuncti-
vitis. It acts in these allergic diseases by inhibiting the
release of chemical inflammatory mediators, such as
prostaglandin E2 (PGE2) and histamine, from mast cells.
Besides these allergic diseases, it is also effective for
keloid and hypertrophic scars. It has been demonstrated
that fibroblasts in keloid and hypertrophic scars produce
much more transforming growth factor-b1( T G F - b1)
than normal fibroblasts [9]. TGF-b1 is known to stimu-
late collagen synthesis [10]. Tranilast suppresses col-
lagen synthesis in keloid or hypertrophic scars, which is
mediated by inhibiting the release of TGF-b1f r o m
fibroblasts [10]. On the other hand, PGE2 and histamine
released from mast cells stimulate the proliferation of
fibroblasts [11,12]. Tranilast inhibits their release from
mast cells [13,14], which in turn inhibits the prolifera-
tion of fibroblasts. Thus, the inhibitory mechanism of
keloid or hypertrophic scar formation by tranilast is
achieved by suppressing the proliferation of fibroblasts
and by inhibiting collagen synthesis. Likewise, fibroblasts
in desmoid tumor have been proven to produce much
more TGF-b1 than normal fibroblasts [15]. By compari-
son with keloid and hypertrophic scars, it is natural to
presume that tranilast should inhibit collagen synthesis
and the proliferation of fibroblasts in desmoid tumor,
leading to shrinkage of the tumor. Since tranilast has
fewer adverse effects, it is superior to the other reported
pharmacotherapies. In addition, tranilast is administered
orally. In the case of chemotherapy with cytotoxic
agents, weekly, bi-weekly or monthly hospital visits or
prolonged hospitalization is necessary for the treatment.
By contrast, a course of treatment with tranilast requires
less frequent hospital visits with no need for prolonged
hospitalization.
Although we cannot determine the efficacy of tranilast
solely from our case report, tranilast seems to be a
potentially desirable therapeutic agent for desmoid
tumor. Further study with a higher number of patients
with desmoid tumor is needed. If the efficacy of this
drug is demonstrated in the future, we will not only use
it as a first-line adjuvant therapy for surgery with inade-
quate surgical margins, but also as a first-line therapy
for unresectable tumors.
Conclusion
Pharmacotherapy with tranilast was effective in a patient
with desmoid tumor on his chest wall. Because tranilast
has substantially fewer adverse effects than cytotoxic
agents, anti-estrogen agents and NSAIDs, it could be a
useful therapeutic agent for desmoid tumor.
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